Search
for
Sort by
Research 31–60 of 53
- Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial
- The Importance of Readability: A Guide to Understanding Alopecia Areata through Multilingual Online Resources
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Alopecia areata: current concepts
- Exploring novel management options for alopecia areata
- The Economic Burden of Alopecia Areata: Evidence from a Survey in Norway and Sweden
- Off-Label Treatment of Alopecia Areata—Retrospective Study
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Gynostemma pentaphyllum Hydrodistillate and Its Major Component Damulin B Promote Hair Growth-Inducing Properties In Vivo and In Vitro via the Wnt/β-Catenin Pathway in Dermal Papilla Cells
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Recent Advances in Drug Development for Hair Loss
- Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
- Recent advances in neuropeptide-related omics and gene editing: Spotlight on NPY and somatostatin and their roles in growth and food intake of fish
- Ritlecitinib (Litfulo)
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Ritlecitinib: First Approval
- Ritlecitinib in severe alopecia areata: a profile of its use
- First drug for severe alopecia recommended by NICE could benefit 14,000 patients
- Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study